Synopsis
Synopsis
0
JDMF
0
KDMF
0
VMF
0
Australia
0
South Africa
0
Listed Dossiers
Annual Reports
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Almogran
2. Almotriptan
3. Axert
1. 181183-52-8
2. Almotriptan Maleate
3. Axert
4. Las 31416 D,l-malate Acid
5. Almotriptan (malate)
6. Almogran
7. Pnu-180638e
8. Almotriptan Malate [usan]
9. Almotriptan D,l-hydrogenmalate
10. Chebi:53781
11. Las-31416 D,l-malate Acid
12. Pjp312605e
13. 181183-52-8(almotriptan Malate)
14. Las-31416-d,l-malate-acid
15. N,n-dimethyl-2-(5-((pyrrolidin-1-ylsulfonyl)methyl)-1h-indol-3-yl)ethan-1-amine 2-hydroxysuccinate
16. 1-(((3-(2-(dimethylamino)ethyl)indol-5-yl)methyl)sulfonyl)pyrrolidine Malate (1:1)
17. 1-(((3-(2-(dimethylamino)ethyl)-1h-indol-5-yl)methyl)sulfonyl)pyrrolidine, Hydroxybutanedioate (1:1)
18. N,n-dimethyl-2-[5-(pyrrolidin-1-ylsulfonylmethyl)-1h-indol-3-yl]ethanamine;2-hydroxybutanedioic Acid
19. Pnu 180638e
20. Unii-pjp312605e
21. Sr-05000001986
22. Axert (tn)
23. Almotriptan Malate (usp)
24. 1-[[[2-(dimethyl-amino)ethyl]-1h-indol-5-yl]methyl]sulfonyl]pyrrolidine Malate
25. Almotriptan Malate (axert)
26. 1-(((3-(2-(dimethylamino)ethyl)-1h-indol-5-yl)methyl)sulfonyl)pyrrolidine, Hydroxybutanedionate (1:1)
27. Mls006010048
28. Schembl221131
29. Almotriptan Maleate [mi]
30. Chembl1200521
31. Dtxsid1044225
32. Almotriptan Malate [vandf]
33. Almotriptan Malate(pnu180638)
34. Hms3651a12
35. Hms3884p05
36. Almotriptan Malate [mart.]
37. Almotriptan Malate [usp-rs]
38. Almotriptan Malate [who-dd]
39. Bcp05632
40. Hy-b0383
41. Mfcd08067740
42. Pnu180638
43. S2096
44. (zznon-labelled)almotriptan-d6 Malate
45. Akos015950790
46. Bcp9000276
47. Ccg-269445
48. Pnu 180638
49. Almotriptan Malate [orange Book]
50. Almotriptan Malate [ep Monograph]
51. Almotriptan Malate [usp Monograph]
52. As-12142
53. Butanedioic Acid, Hydroxy-, Compd. With 1-(((3-(2-(dimethylamino)ethyl)-1h-indol-5-yl)methyl)sulfonyl)pyrrolidine (1:1)
54. Smr004701216
55. Ft-0661519
56. Sw219418-1
57. D02825
58. F14758
59. J-011571
60. Sr-05000001986-2
61. Q27124206
62. 1-(((3-(2-(dimethylamino)ethyl)indol-5-yl)methyl)sulfonyl)pyrrolidine Malate
63. 3-[2-(dimethylamino)ethyl]-5-(pyrrolidin-1-ylsulfonylmethyl )-1h-indole Malate
64. 1-(((3-(2-(dimethylamino)ethyl)-1h-indol-5-yl)methyl)sulfonyl)pyrrolidine Hydroxybutanedioate
65. Butanedioic Acid, 2-hydroxy-, Compd. With N,n-dimethyl-5-[(1-pyrrolidinylsulfonyl)methyl]-1h-indole-3-ethanamine (1:1)
Molecular Weight | 469.6 g/mol |
---|---|
Molecular Formula | C21H31N3O7S |
Hydrogen Bond Donor Count | 4 |
Hydrogen Bond Acceptor Count | 9 |
Rotatable Bond Count | 9 |
Exact Mass | 469.18827151 g/mol |
Monoisotopic Mass | 469.18827151 g/mol |
Topological Polar Surface Area | 160 Ų |
Heavy Atom Count | 32 |
Formal Charge | 0 |
Complexity | 612 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 1 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 2 | |
---|---|
Drug Name | Almotriptan malate |
Drug Label | AXERT (almotriptan malate) Tablets contain almotriptan malate, a selective 5-hydroxytryptamine1B/1D (5-HT1B/1D) receptor agonist. Almotriptan malate is chemically designated as 1-[[[3-[2-(Dimethylamino)ethyl]-1H-indol-5-yl]methyl]sulfonyl]pyrrolidi... |
Active Ingredient | Almotriptan malate |
Dosage Form | Tablet |
Route | oral |
Strength | 6.25mg; 12.5mg |
Market Status | Tentative Approval |
Company | Teva Pharms |
2 of 2 | |
---|---|
Drug Name | Almotriptan malate |
Drug Label | AXERT (almotriptan malate) Tablets contain almotriptan malate, a selective 5-hydroxytryptamine1B/1D (5-HT1B/1D) receptor agonist. Almotriptan malate is chemically designated as 1-[[[3-[2-(Dimethylamino)ethyl]-1H-indol-5-yl]methyl]sulfonyl]pyrrolidi... |
Active Ingredient | Almotriptan malate |
Dosage Form | Tablet |
Route | oral |
Strength | 6.25mg; 12.5mg |
Market Status | Tentative Approval |
Company | Teva Pharms |
Serotonin Receptor Agonists
Endogenous compounds and drugs that bind to and activate SEROTONIN RECEPTORS. Many serotonin receptor agonists are used as ANTIDEPRESSANTS; ANXIOLYTICS; and in the treatment of MIGRAINE DISORDERS. (See all compounds classified as Serotonin Receptor Agonists.)
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
77
PharmaCompass offers a list of Almotriptan Malate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Almotriptan Malate manufacturer or Almotriptan Malate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Almotriptan Malate manufacturer or Almotriptan Malate supplier.
PharmaCompass also assists you with knowing the Almotriptan Malate API Price utilized in the formulation of products. Almotriptan Malate API Price is not always fixed or binding as the Almotriptan Malate Price is obtained through a variety of data sources. The Almotriptan Malate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A LAS 31416 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of LAS 31416, including repackagers and relabelers. The FDA regulates LAS 31416 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. LAS 31416 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of LAS 31416 manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A LAS 31416 supplier is an individual or a company that provides LAS 31416 active pharmaceutical ingredient (API) or LAS 31416 finished formulations upon request. The LAS 31416 suppliers may include LAS 31416 API manufacturers, exporters, distributors and traders.
click here to find a list of LAS 31416 suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A LAS 31416 DMF (Drug Master File) is a document detailing the whole manufacturing process of LAS 31416 active pharmaceutical ingredient (API) in detail. Different forms of LAS 31416 DMFs exist exist since differing nations have different regulations, such as LAS 31416 USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A LAS 31416 DMF submitted to regulatory agencies in the US is known as a USDMF. LAS 31416 USDMF includes data on LAS 31416's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The LAS 31416 USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of LAS 31416 suppliers with USDMF on PharmaCompass.
A LAS 31416 CEP of the European Pharmacopoeia monograph is often referred to as a LAS 31416 Certificate of Suitability (COS). The purpose of a LAS 31416 CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of LAS 31416 EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of LAS 31416 to their clients by showing that a LAS 31416 CEP has been issued for it. The manufacturer submits a LAS 31416 CEP (COS) as part of the market authorization procedure, and it takes on the role of a LAS 31416 CEP holder for the record. Additionally, the data presented in the LAS 31416 CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the LAS 31416 DMF.
A LAS 31416 CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. LAS 31416 CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of LAS 31416 suppliers with CEP (COS) on PharmaCompass.
A LAS 31416 written confirmation (LAS 31416 WC) is an official document issued by a regulatory agency to a LAS 31416 manufacturer, verifying that the manufacturing facility of a LAS 31416 active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting LAS 31416 APIs or LAS 31416 finished pharmaceutical products to another nation, regulatory agencies frequently require a LAS 31416 WC (written confirmation) as part of the regulatory process.
click here to find a list of LAS 31416 suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing LAS 31416 as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for LAS 31416 API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture LAS 31416 as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain LAS 31416 and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a LAS 31416 NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of LAS 31416 suppliers with NDC on PharmaCompass.
LAS 31416 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of LAS 31416 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right LAS 31416 GMP manufacturer or LAS 31416 GMP API supplier for your needs.
A LAS 31416 CoA (Certificate of Analysis) is a formal document that attests to LAS 31416's compliance with LAS 31416 specifications and serves as a tool for batch-level quality control.
LAS 31416 CoA mostly includes findings from lab analyses of a specific batch. For each LAS 31416 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
LAS 31416 may be tested according to a variety of international standards, such as European Pharmacopoeia (LAS 31416 EP), LAS 31416 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (LAS 31416 USP).